Unity Biotechnology expands ongoing UBX0101 Phase 1 study

Unity Biotechnology announced further expansion of the Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis of the knee with a cohort of an additional 24 patients at the highest evaluated dose, or Part B. Part B is intended to supplement the initial Phase 1 trial, or Part A, by further evaluating the impact of UBX0101 on specific pro-inflammatory and extracellular matrix modifying factors within the Senescence-Associated Secretory Phenotype.
https://thefly.com/landingPageNews.php?id=2851893